CervoMed Inc
CRVO
NASDAQ
Biotechnology
$2.73
USD
-0.20 (-6.83%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $45.36M
Volume 604.8K
Revenue
$331,295
TTM
-95.7%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-30.35M
TTM
-34.2%
YoY
Operating Cash Flow
$-27.98M
TTM
-20.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 1.8 | 0.3 | 0.0 | 0.0 | 0.0 |
YoY Growth | -46.6% | -83.4% | -99.6% | -100.0% | -100.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 1.8 | 0.3 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 3.3 | 2.3 | 2.5 | 3.0 | 2.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 8.4 | 8.4 | 8.3 | 8.1 | 6.7 |
Operating Income | -6.6 | -8.0 | -8.3 | -8.1 | -6.7 |
EBITDA | -6.6 | -8.0 | -8.3 | -8.1 | -6.7 |
Other Income / Expense | -0.0 | -0.0 | 0.0 | -0.0 | 0.0 |
Total Other Income / Expense | 0.4 | 0.3 | 0.2 | 0.1 | 0.1 |
Income Before Income Taxes | -6.3 | -7.7 | -8.1 | -8.0 | -6.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -6.3 | -7.7 | -8.1 | -8.0 | -6.6 |
Consolidated Net Income / Loss | -6.3 | -7.7 | -8.1 | -8.0 | -6.6 |
Net Income Attributable to Common Shareholders | -6.3 | -7.7 | -8.1 | -8.0 | -6.6 |
Basic EPS | -$0.70 | -$0.84 | -$0.87 | -$0.86 | -$0.64 |
Diluted EPS | -$0.70 | -$0.84 | -$0.87 | -$0.86 | -$0.64 |
Basic Shares Outstanding | 9.0M | 9.3M | 9.3M | 9.3M | 10.2M |
Diluted Shares Outstanding | 9.0M | 9.3M | 9.3M | 9.3M | 10.2M |